Related Experiment Video

Updated: Dec 6, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.6K

Should triple-positive breast cancer be recognized as a distinct subtype?

Maria Vittoria Dieci1,2, Valentina Guarneri1,2

  • 1Department of Surgery, Oncology and Gastroenterology, University of Padova , Padova, Italy.

Expert Review of Anticancer Therapy
|October 6, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Breast cancerher2-positivehormone receptortargeted therapytriple positive

More Related Videos

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.1K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K

Related Experiment Videos

Last Updated: Dec 6, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.6K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.1K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.9K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K

Articles linked to this work by shared authors, journal, and citation graph.

Comparing Real-Time PCR and Amplicon-Based NGS for Routine EGFR Liquid Biopsy Profiling.

Diagnostics (Basel, Switzerland)·2026

Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.

European journal of cancer (Oxford, England : 1990)·2026

Analysis of SLFN11 expression in small cell lung cancer, carcinoids and large cell neuroendocrine carcinoma: insights into lung neuroendocrine neoplasms.

Lung cancer (Amsterdam, Netherlands)·2026

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Adjuvant Approaches in Fully Resected Stage III and IV Cutaneous Melanoma: Where Are We Now?

Cancers·2026

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026

AA amyloidosis as a renal immune-related adverse event of immune checkpoint inhibitors: mechanisms, diagnosis, and management.

Expert review of anticancer therapy·2026

Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing.

Expert review of anticancer therapy·2026

The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches.

Expert review of anticancer therapy·2026

Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection.

Expert review of anticancer therapy·2026

An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal.

Expert review of anticancer therapy·2026

Overcoming therapeutic resistance in biliary tract cancer: from resistance mechanisms to dynamic precision oncology - a narrative review.

Expert review of anticancer therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us